Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Quick Stats
Mar 30, 202655.8
AI Score
HOLD0.29
Volume Ratio
May 14, 2026
Next Earnings
14
+ve Days (30d)
16
-ve Days (30d)
NTLA Stock Summary
Last updated
NTLA is currently trading at $11.82, positioned below its 200-day moving average of $12.72, suggesting bearish momentum. The stock has a 52-week range of $5.9 to $28.25.
Technical Analysis: The 50-day moving average stands at $13.16, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates NTLA at 55.8/100 with a HOLD recommendation.
NTLA Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
NTLA Price vs Max Options Open Interest
NTLA Max Change In Options Open Interest
NTLA Options - Sort by Max open Interest (near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NTLA Daily Out of Money Options - Sort by Max open Interest (near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NTLA Daily In the Money Options - Sort by Max open Interest (near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
NTLA Most Active Options by Volume(near term)
30th March 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Intellia Therapeutics, Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
NTLA Moving Averages Analysis
NTLA (Intellia Therapeutics, Inc) Simple Moving Averages
Moving Averages are last updated Mar 30, 2026
| Days | MA |
|---|---|
| 10 | 12.93 |
| 20 | 13.13 |
| 30 | 13.22 |
| 50 | 13.16 |
| 100 | 11.37 |
| 200 | 12.72 |
NTLA Fundamental Analysis
| P/E (Forward) | 0 |
| P/E (Trailing) | -- |
| Market Cap ($) | 1.6 billion |
| Earnings/Share ($) | -3.81 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -3.5558 |
| EPS Estimate Next Year ($) | -2.921 |
| WallStreet Target Price ($) | 25.2857 |
| Most Recent Quarter |